Skip to main content

Poxel to Report Its 2023 Annual Results by the End of April 2024

  • Exclusive discussions and finalization of related documentation underway with a leading investor to monetize royalties from TWYMEEG® (Imeglimin) sales in Japan
  • Cash runway estimated to be sufficient until the completion of the transaction expected by the end of April, including tranches already drawn or fully available on the equity-linked financing facility with IRIS

Regulatory News:

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.

The Company, which has made significant progress in securing additional financing, is targeting to close, by the end of April, a transaction relating to the monetization of royalties from TWYMEEG® (Imeglimin) sales in Japan.

Poxel expects that its financial resources will be sufficient to maintain its operations until the finalization of this monetization transaction.

The Company will communicate its new financial calendar in April 2024 upon completion of this transaction.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.

Contacts

Contacts - Investor relations / Media



NewCap

Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé

poxel@newcap.eu

+33 1 44 71 94 94

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.